and he can't Look beyond the Headlines ..... and see what Biden's Legislation is Doing !!! He's anotherYou have absolutely no idea what a virus does to a species immediately after host shift, do you ? You have zero knowledge of the behavior of the 42 previously identified novel coronavirus , do you ?
if it is eventually discovered that part of the gain of function tweaking was in the creation of the long latency period, in combination with doing the work in a level 2 lab to save on level 4 costs, well, that is sociopathic behavior. Anybody responsible for putting it on that path needs to be severely punished.
The Inflation Reduction Act Is Already Killing Potential Cures
Opinion | The Inflation Reduction Act Is Already Killing Potential Cures
The law’s price controls do away with incentives for research and development of life-saving drugs.
www.wsj.com
It may take years before we can fully appreciate the impact of the Inflation Reduction Act on the pharmaceutical industry, but we’re already getting signs of the damage. While Democrats boast that they’ve given Medicare the power to “negotiate” drug prices, the effect has been to saddle manufacturers with a complex and ill-conceived price-setting scheme. In response, many have canceled drug-development programs, resulting in an unfortunate but predictable loss for patients nationwide.
One poorly crafted provision is driving companies away from research into treating rare diseases. In its Oct. 27 earnings statement, Alnylam announced it is suspending development of a treatment for Stargardt disease, a rare eye disorder, because of the company’s need “to evaluate impact of the Inflation Reduction Act.” Alnylam’s decision turns on a provision in the Democrats’ bill that exempts from price-setting negotiations drugs that treat only one rare disease. The company’s drug is currently marketed as treating only amyloidosis, and thus is exempt from Medicare’s price setting. If Alnylam proceeded with research into treating Stargardt, it would lose its exemption.
That disincentive might be most pronounced in cancer treatments. On Tuesday, Eli Lilly announced it is canceling work on a drug that had been undergoing studies for certain blood cancers. “In light of the Inflation Reduction Act,” the company wrote to Endpoints News, “this program no longer met our threshold for continued investment.”
When pharmaceutical companies develop cancer drugs, they usually first develop them for a single indication. Only after the first approval do they research additional indications. Merck’s Keytruda, which successfully treated President Jimmy Carter, was first approved for advanced melanoma in 2014.